-$0.42 EPS Expected for Iovance Biotherapeutics Inc (NASDAQ:IOVA) This Quarter

Share on StockTwits

Equities analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to announce earnings per share (EPS) of ($0.42) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings, with estimates ranging from ($0.45) to ($0.40). Iovance Biotherapeutics posted earnings per share of ($0.27) in the same quarter last year, which indicates a negative year over year growth rate of 55.6%. The firm is expected to issue its next earnings results on Wednesday, February 26th.

According to Zacks, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.50) per share for the current financial year, with EPS estimates ranging from ($1.53) to ($1.47). For the next fiscal year, analysts forecast that the company will post earnings of ($1.70) per share, with EPS estimates ranging from ($2.32) to ($0.61). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Iovance Biotherapeutics.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.01).

A number of equities research analysts have weighed in on IOVA shares. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a report on Thursday, November 21st. Chardan Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of Iovance Biotherapeutics in a report on Thursday, November 21st. Stifel Nicolaus started coverage on Iovance Biotherapeutics in a report on Monday, September 30th. They issued a “buy” rating and a $27.00 target price on the stock. BidaskClub raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday. Finally, Jefferies Financial Group set a $33.00 target price on Iovance Biotherapeutics and gave the company a “buy” rating in a report on Monday, August 26th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $29.27.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC acquired a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $29,000. Aperio Group LLC acquired a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $86,000. Meeder Asset Management Inc. boosted its holdings in shares of Iovance Biotherapeutics by 453.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 6,356 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 5,207 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Iovance Biotherapeutics by 14.9% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,700 shares of the biotechnology company’s stock valued at $189,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $212,000. 97.27% of the stock is currently owned by institutional investors.

Shares of IOVA stock traded down $0.15 during trading hours on Friday, reaching $24.72. The company’s stock had a trading volume of 1,079,985 shares, compared to its average volume of 1,397,611. The firm’s 50 day simple moving average is $21.94 and its 200-day simple moving average is $21.19. The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of -19.46 and a beta of 1.99. Iovance Biotherapeutics has a fifty-two week low of $7.26 and a fifty-two week high of $26.59. The company has a quick ratio of 10.61, a current ratio of 10.61 and a debt-to-equity ratio of 0.02.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Featured Story: What moving averages are used to define a golden cross?

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Deutsche Bank  PT Set at €5.00 by Barclays
Deutsche Bank PT Set at €5.00 by Barclays
Bayer  Given a €75.00 Price Target by JPMorgan Chase & Co. Analysts
Bayer Given a €75.00 Price Target by JPMorgan Chase & Co. Analysts
William Hill  Rating Reiterated by Peel Hunt
William Hill Rating Reiterated by Peel Hunt
Warehouse REIT  Rating Reiterated by Peel Hunt
Warehouse REIT Rating Reiterated by Peel Hunt
Weir Group  Rating Reiterated by Deutsche Bank
Weir Group Rating Reiterated by Deutsche Bank
Peel Hunt Reiterates “Buy” Rating for Ten Entertainment Group
Peel Hunt Reiterates “Buy” Rating for Ten Entertainment Group


© 2006-2020 Ticker Report